Beam Therapeutics Announces Board and Executive Changes
Ticker: BEAM · Form: 8-K · Filed: Dec 6, 2024
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Beam Therapeutics shakes up its board and exec comp. New faces, new pay structures.
AI Summary
Beam Therapeutics Inc. announced on December 5, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. These changes are effective as of December 5, 2024.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- December 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, Massachusetts (location) — Address of Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What are the key changes in compensatory arrangements?
The filing notes updates to compensatory arrangements for certain officers but does not detail the specifics of these changes.
When were these changes effective?
The changes reported in this Form 8-K were effective as of December 5, 2024.
What is the primary business of Beam Therapeutics Inc.?
Beam Therapeutics Inc. is involved in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.
Filing Stats: 1,493 words · 6 min read · ~5 pages · Grade level 12.8 · Accepted 2024-12-06 07:06:28
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
- $575,000 — is entitled to an annual base salary of $575,000. Mr. Emany is entitled to receive a one
- $325,000 — one-time sign-on bonus in the amount of $325,000 and is also eligible for an annual ince
Filing Documents
- d888673d8k.htm (8-K) — 34KB
- d888673dex991.htm (EX-99.1) — 10KB
- g888673g1205030634414.jpg (GRAPHIC) — 3KB
- 0001193125-24-271965.txt ( ) — 170KB
- beam-20241205.xsd (EX-101.SCH) — 3KB
- beam-20241205_lab.xml (EX-101.LAB) — 17KB
- beam-20241205_pre.xml (EX-101.PRE) — 11KB
- d888673d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press Release Issued by Beam Therapeutics Inc. on December 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 6, 2024 Beam Therapeutics Inc. By: /s/ John Evans Name: John Evans Title: Chief Executive Officer